<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">99040</article-id><article-id pub-id-type="doi">10.7554/eLife.99040</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.99040.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Recurrent disruption of tumour suppressor genes in cancer by somatic mutations in cleavage and polyadenylation signals</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kainov</surname><given-names>Yaroslav</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0664-9102</contrib-id><email>yaroslav.kainov@kcl.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hamid</surname><given-names>Fursham</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6846-7382</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Makeyev</surname><given-names>Eugene V</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6034-6896</contrib-id><email>eugene.makeyev@kcl.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>Centre for Developmental Neurobiology, King’s College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>Department of Medical and Molecular Genetics, King’s College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Choi</surname><given-names>Murim</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution></institution-wrap><country>Republic of Korea</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Choi</surname><given-names>Murim</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h9pn542</institution-id><institution>Seoul National University</institution></institution-wrap><country>Republic of Korea</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>11</day><month>12</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP99040</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-06-24"><day>24</day><month>06</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-06-28"><day>28</day><month>06</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.06.23.600297"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-08-22"><day>22</day><month>08</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.99040.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-11-13"><day>13</day><month>11</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.99040.2"/></event></pub-history><permissions><copyright-statement>© 2024, Kainov et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Kainov et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-99040-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-99040-figures-v1.pdf"/><abstract><p>The expression of eukaryotic genes relies on the precise 3'-terminal cleavage and polyadenylation of newly synthesized pre-mRNA transcripts. Defects in these processes have been associated with various diseases, including cancer. While cancer-focused sequencing studies have identified numerous driver mutations in protein-coding sequences, noncoding drivers – particularly those affecting the cis-elements required for pre-mRNA cleavage and polyadenylation – have received less attention. Here, we systematically analysed somatic mutations affecting 3'UTR polyadenylation signals in human cancers using the Pan-Cancer Analysis of Whole Genomes (PCAWG) dataset. We found a striking enrichment of cancer-specific somatic mutations that disrupt strong and evolutionarily conserved cleavage and polyadenylation signals within tumour suppressor genes. Further bioinformatics and experimental analyses conducted as a part of our study suggest that these mutations have a profound capacity to downregulate the expression of tumour suppressor genes. Thus, this work uncovers a novel class of noncoding somatic mutations with significant potential to drive cancer progression.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>somatic mutations</kwd><kwd>cleavage</kwd><kwd>tumour suppressor</kwd><kwd>polyadenylation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/V006258/1</award-id><principal-award-recipient><name><surname>Makeyev</surname><given-names>Eugene V</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/R001049/1</award-id><principal-award-recipient><name><surname>Makeyev</surname><given-names>Eugene V</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Somatic mutations frequently disrupt cleavage and polyadenylation signals in tumour suppressor genes in human cancers, likely contributing to tumour progression.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Most eukaryotic mRNAs are modified by the addition of a 5’-terminal 7-methylguanosine cap, splicing of intronic sequences, and 3'-terminal cleavage and polyadenylation. The cleavage and polyadenylation reactions are tightly coupled with transcription termination and the release of newly synthesized transcripts from RNA polymerase II. Therefore, precise cleavage and polyadenylation are critical for the production of mature mRNAs. Mechanistically, these reactions require a co-transcriptional assembly of a multisubunit protein complex at the corresponding cis-regulatory sequences near the pre-mRNA cleavage site (CS) (<xref ref-type="bibr" rid="bib33">Tian and Manley, 2017</xref>; <xref ref-type="bibr" rid="bib22">Neve et al., 2017</xref>; <xref ref-type="bibr" rid="bib28">Shi et al., 2009</xref>). A key cis-element guiding the assembly of the cleavage and polyadenylation machinery is the polyadenylation signal (PAS). The most common PAS sequences in mammals are AATAAA and ATTAAA hexamers, although their single nucleotide-substituted variants may function in some cases (<xref ref-type="bibr" rid="bib24">Proudfoot, 1991</xref>; <xref ref-type="bibr" rid="bib1">Beaudoing et al., 2000</xref>).</p><p>Earlier studies have emphasized the importance of pre-mRNA cleavage/polyadenylation in the context of human diseases. For example, alternative cleavage/polyadenylation has been proposed to modulate the expression of oncogenes and tumour suppressors in different types of cancer (<xref ref-type="bibr" rid="bib21">Mayr and Bartel, 2009</xref>; <xref ref-type="bibr" rid="bib17">Lee et al., 2018</xref>). Germline mutations affecting polyadenylation signals can play a role in genetic disorders (<xref ref-type="bibr" rid="bib13">Higgs et al., 1983</xref>; <xref ref-type="bibr" rid="bib4">Bogard et al., 2019</xref>; <xref ref-type="bibr" rid="bib2">Bennett et al., 2001</xref>) and increase cancer susceptibility (<xref ref-type="bibr" rid="bib31">Stacey et al., 2011</xref>; <xref ref-type="bibr" rid="bib18">Li et al., 2023</xref>). Notably, although the role of somatic mutations affecting polyadenylation signals has been investigated for individual genes in a limited number of tumour samples (<xref ref-type="bibr" rid="bib35">Wiestner et al., 2007</xref>; <xref ref-type="bibr" rid="bib29">Shlien et al., 2016</xref>), a systematic characterisation of the role of this type of mutation in cancer has not been carried out.</p><p>Large-scale genome sequencing studies have identified numerous cancer driver and driver-like mutations within protein-coding sequences (<xref ref-type="bibr" rid="bib14">ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020</xref>). Such mutations have also been mapped to noncoding regions; however, existing research has primarily focused on promoters, enhancers, and splicing signals (<xref ref-type="bibr" rid="bib7">Cao et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Zhao et al., 2021</xref>; <xref ref-type="bibr" rid="bib27">Sherman et al., 2022</xref>; <xref ref-type="bibr" rid="bib26">Rheinbay et al., 2020</xref>; <xref ref-type="bibr" rid="bib6">Calabrese et al., 2020</xref>), rather than sequences regulating pre-mRNA cleavage and polyadenylation.</p><p>Here, we conducted a systematic genome-wide analysis of somatic single-nucleotide variants (SNVs) affecting the PAS elements in mRNA 3' untranslated regions (3'UTRs) in cancer cells. Using a large tumour whole-genome sequencing dataset, the PCAWG (<xref ref-type="bibr" rid="bib14">ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020</xref>), we found that strong and evolutionarily conserved cleavage/polyadenylation signals are often disrupted by cancer-specific SNVs. Strikingly, such mutations are significantly enriched in tumour suppressor genes. We further provide evidence that such mutations can substantially decrease the expression of tumour suppressor genes in cancer cells. Overall, our work identifies a novel class of noncoding somatic mutations with driver-like properties in cancer.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Somatic mutations often disrupt cleavage and polyadenylation sequences in cancer</title><p>We first analysed SNVs neighbouring annotated human cleavage and polyadenylation positions (paSNVs) in 3’UTRs from the PolyA_DB3 database (<xref ref-type="bibr" rid="bib34">Wang et al., 2018</xref>). We considered two distinct cohorts: ‘Normal’ paSNVs from a healthy human population (the 1000 Genomes phase 3 data <xref ref-type="bibr" rid="bib9">Fairley et al., 2020</xref>) and ‘Cancer’ paSNVs from the whole-genome sequencing of cancer samples (PCAWG) (<xref ref-type="bibr" rid="bib14">ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020</xref>).</p><p>For each paSNV, we calculated the change in cleavage/polyadenylation efficiency using the APARENT2 neural network model, which has been shown to infer this statistic more accurately than earlier approaches (<xref ref-type="bibr" rid="bib19">Linder et al., 2022</xref>). We additionally assessed the loss and gain of the two strongest polyadenylation signals, AATAAA and ATTAAA (referred to as AWTAAA throughout this study; <xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>paSNVs disrupting cleavage/polyadenylation signals are depleted in the normal population.</title><p>(<bold>A</bold>) Bioinformatics workflow used to analyse the effect of paSNVs on pre-mRNA cleavage and polyadenylation. (<bold>B</bold>) Top, effects of UP- and DOWN-paSNVs on the APARENT2 score (mean ± SEM) as a function of their position with respect to annotated pre-mRNA cleavage sites (CSs). Bottom, combined distribution of AWTAAA-affecting paSNVs in both datasets. (<bold>C</bold>) Box plot showing that paSNVs disrupting polyadenylation signals are significantly less frequent compared to control groups of events in the normal population. (<bold>D</bold>) paSNVs disrupting polyadenylation signals are enriched for singletons, consistent with purifying selection against such events in the normal population.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99040-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Distribution of cleavage/polyadenylation signal-disrupting mutations in the normal population (1000 genomes dataset).</title><p>(<bold>A–B</bold>) As expected, (<bold>A</bold>) AWTAAA-containing paSNVs tend to be associated with a relatively high APARENT2 score and (<bold>B</bold>) the loss or gain of AATAAA typically reduced or increased the score, respectively. (<bold>C</bold>) Box plot comparison of normal-population allele frequencies of cleavage/polyadenylation signal-disrupting mutations defined by considering only AWTAAA gain/loss, only APARENT2 score changes, or both (DOWN-paSNVs). (<bold>D</bold>) Bar plot comparison of normal-population fractions of singletons for cleavage/polyadenylation signal-disrupting mutations defined by considering only AWTAAA gain/loss, only APARENT2 score changes, or both (DOWN-paSNVs).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99040-fig1-figsupp1-v1.tif"/></fig></fig-group><p>As expected, paSNVs predicted to have a strong impact on cleavage/polyadenylation were often situated immediately upstream of a CS, with most of them affecting AWTAAA hexamers (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Furthermore, the presence of AATAAA or ATTAAA in polyadenylation signals tended to be associated with a high APARENT2 score (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), and the loss or gain of AATAAA led to a significantly stronger decrease or increase in the score, respectively, compared to other mutations (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). This provided internal validation of the algorithm’s performance in our hands.</p><p>We then categorized all paSNVs into three groups: (1) upregulating cleavage/polyadenylation (UP-paSNVs), defined as events with a ≥1 increase in the APARENT2 score (log odds ratio, or LOR) and creating an AWTAAA hexamer; (2) downregulating cleavage/polyadenylation (DOWN-paSNVs; LOR≤–1 and disrupting an AWTAAA); and (3) the remaining annotated cleavage position-adjacent paSNVs (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The latter group served as a background control (BG-paSNVs) in our subsequent analyses.</p><p>Consistent with the earlier studies (<xref ref-type="bibr" rid="bib19">Linder et al., 2022</xref>; <xref ref-type="bibr" rid="bib15">Kainov et al., 2016</xref>; <xref ref-type="bibr" rid="bib11">Findlay et al., 2022</xref>), we observed a pronounced negative selection against the DOWN-paSNVs in the Normal dataset (<xref ref-type="fig" rid="fig1">Figure 1C, D</xref>). This category showed significantly decreased allele frequencies in comparison to the BG-paSNVs and was enriched for singletons (unique variants in the analysed dataset). This effect was more evident when considering changes in both the score and the hexamer composition (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C, D</xref>).</p><p>Notably, a comparison of the Normal and Cancer datasets showed that cancer somatic mutations, on average, had a stronger effect on the polyadenylation efficiency in both the UP- and DOWN-paSNV groups (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; LOR sample variance 0.115 in cancer vs 0.0876 in normal). DOWN-paSNVs were significantly enriched in cancer compared to the normal population data (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We also observed that mutations disrupting AWTAAA hexamers in 3'UTRs tended to occur near annotated cleavage sites in cancer (<xref ref-type="fig" rid="fig2">Figure 2B</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Cancer somatic mutations tend to disrupt functional cleavage/polyadenylation signals.</title><p>(<bold>A</bold>) Bar plot showing enrichment of paSNVs disrupting polyadenylation signals among cancer somatic mutations. (<bold>B</bold>) Bar plot showing enrichment of single-nucleotide variants (SNVs) affecting AWTAAA sequences in 3’UTRs close to annotated cleavage sites (CSs) among cancer somatic mutations. (<bold>C</bold>) Box plot showing that somatic mutations disrupt stronger cleavage/polyadenylation signals in cancer. (<bold>D</bold>) paSNVs disrupting polyadenylation signals occur in more evolutionary conserved regions in cancer (mean PhastCons score in 15-nt window centred at SNVs). (<bold>E</bold>) Distribution of DOWN-paSNVs across cancer types in the Pan-Cancer Analysis of Whole Genomes (PCAWG) project.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99040-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Cancer somatic DOWN-paSNVs often occur in evolutionarily conserved regions.</title><p>The plot is generated similarly to <xref ref-type="fig" rid="fig2">Figure 2D</xref> except the conservation was calculated for the exact single-nucleotide variant (SNV) position.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99040-fig2-figsupp1-v1.tif"/></fig></fig-group><p>Interestingly, cancer-specific DOWN-paSNVs affected cleavage/polyadenylation signals with higher APARENT2 scores (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Furthermore, DOWN-paSNVs tended to affect more evolutionarily conserved sequences in the Cancer dataset compared to the Normal control (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). In total, we identified 1614 distinct cancer somatic DOWN-paSNVs affecting 1570 cleavage/polyadenylation events in 1460 genes in 602 tumours, i.e., 22.7% of all tumour samples in PCAWG (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Notably, nearly half of the DOWN-paSNVs originated from colorectal adenocarcinoma, with the remaining mutations distributed across a wide range of other cancer types (<xref ref-type="fig" rid="fig2">Figure 2E</xref>).</p><p>We concluded that mutations disrupting functional cleavage/polyadenylation signals are abundant in cancer cells despite being subject to strong purifying selection in a healthy population.</p></sec><sec id="s2-2"><title>Cancer-specific mutations in cleavage and polyadenylation sequences are enriched in tumour suppressor genes</title><p>There are two possible explanations for the enrichment of DOWN-paSNV events in cancer: (1) an increase in the overall mutation load and (2) positive selection for such mutations. Since the latter possibility may increase the incidence of mutations in cancer driver genes, we analysed the distribution of DOWN-paSNVs within genes from the Cancer Gene Census (<xref ref-type="bibr" rid="bib32">Tate et al., 2019</xref>). This revealed a remarkable over-representation of the DOWN-paSNVs in tumour suppressor genes, with the magnitude of this effect being greater than the corresponding enrichment of nonsense mutations (SNVs creating a premature translation termination codon) (<xref ref-type="fig" rid="fig3">Figure 3A, B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Somatic cancer mutations often disrupt cleavage/polyadenylation signals in tumour suppressor genes.</title><p>(<bold>A</bold>) Stacked bar plot showing enrichment of single-nucleotide variants (SNVs) disrupting polyadenylation signals (DOWN-paSNVs) in tumour suppressors in cancer. (<bold>B–C</bold>) Overrepresentation of (<bold>B</bold>) tumour suppressors but not (<bold>C</bold>) oncogenes among genes with cancer somatic DOWN-paSNVs, as compared to genes with cancer somatic BG-paSNVs. Fractions of tumour suppressors and oncogenes are also shown for all genes and genes containing cancer somatic nonsense (premature stop codons), missense (altered amino acid residues) and synonymous (synonymous codons) mutations. Note that the enrichment of tumour suppressors is stronger for DOWN-paSNVs compared to nonsense mutations. (<bold>C</bold>) Top 10 GO Biological Process terms significantly enriched in genes with cancer somatic DOWN-paSNVs. Note the enrichment of apoptosis- and cell death-related functions. (<bold>D</bold>) GO Molecular Function terms significantly enriched in genes with cancer somatic DOWN-paSNVs.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99040-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Cancer somatic DOWN-paSNVs often reside in genes with tumour-suppressive functions.</title><p>Normalized stacked bar plot showing enrichment of single-nucleotide variants (SNVs) disrupting polyadenylation signals (DOWN-paSNVs) in tumour suppressors for Census genes only. Note that nonsense mutations show a similar to DOWN-paSNVs enrichment in tumour suppressors, but not oncogenes. Conversely, UP-paSNVs are enriched in oncogenes but not tumour suppressors.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99040-fig3-figsupp1-v1.tif"/></fig></fig-group><p>Notably, DOWN-paSNVs were not enriched in the oncogenes (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), in line with the disruptive nature of such mutations under normal conditions (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Conversely, oncogenes but not tumour suppressors showed some enrichment for UP-paSNVs (<xref ref-type="fig" rid="fig3">Figure 3A</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p><p>Overall, DOWN-paSNVs were found to affect 38 tumour suppressor genes, i.e., 14.3% of all genes in this category in the Census dataset. In several cases, including <italic>LRP1B</italic> and <italic>FOXO1</italic>, which are known to act as tumour suppressors in certain cancers, the same signal/polyadenylation signal was disrupted by the same or different mutations in more than one sample (see columns Mut_Recurrence and Signal_Recurrence in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Consistent with tumour suppressors being a major target of DOWN-paSNVs, genes with this type of mutations were significantly enriched for apoptosis-related functions (<xref ref-type="fig" rid="fig3">Figure 3D</xref>; e.g. tumour suppressors <italic>CASP9</italic> or <italic>FHIT</italic>). We also detected the enrichment of proteins interacting with the ubiquitination pathway (<xref ref-type="fig" rid="fig3">Figure 3D, E</xref>; e.g. tumour suppressors <italic>SMAD2</italic>, <italic>APC,</italic> and <italic>AXIN1</italic>).</p><p>To independently confirm the functional impact of DOWN-paSNVs in cancer, we compared the mutational excess of different types of somatic mutations using DigDriver (<xref ref-type="bibr" rid="bib27">Sherman et al., 2022</xref>), a neural network-based method that accounts for cancer-specific mutation rates. This analysis revealed a significantly higher observed-to-expected mutation rate for DOWN-paSNV events in cancer compared to the BG-paSNV group (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). DOWN-paSNVs tended to be enriched in tumour suppressor genes, consistent with positive selection for these events in cancer (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). No such enrichment was detected in oncogenes (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Disruption of cleavage/polyadenylation signals in tumour suppressors, along with other damaging mutations, may facilitate cancer progression.</title><p>(<bold>A–B</bold>) Enrichment of different groups of cancer somatic single-nucleotide variants (SNVs) in (<bold>A</bold>) tumour suppressors and (<bold>B</bold>) oncogenes calculated using DigDriver relative to genes not listed in Cancer Census (non-Census) and presented with 95% confidence intervals. Note that DOWN-paSNVs and nonsense mutations are enriched in tumour suppressors but not in oncogenes. In contrast, oncogenes are often affected by missense mutations, as expected. (<bold>C</bold>) Cancer somatic DOWN-paSNVs co-occur in the same tumour with non-synonymous damaging SNVs, a group of somatic mutations defined in <xref ref-type="bibr" rid="bib6">Calabrese et al., 2020</xref>, more often than BG-paSNVs. Note that the co-occurrence is particularly high for tumour suppressors. (<bold>D</bold>) The overall frequency of non-synonymous damaging SNVs is significantly higher in the DOWN-paSNV-containing group compared to the DOWN-paSNV-lacking group of tumour suppressor genes.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99040-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Cancer somatic DOWN-paSNVs are enriched for statistically significant DigDriver events (BH-adjusted p&lt;0.01), suggesting that they may be under positive selection in cancer.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99040-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Wild-type tumour suppressor genes tend to have efficient cleavage/polyadenylation signals.</title><p>(<bold>A</bold>) Box plot showing that wild-type tumour suppressors have stronger cleavage/polyadenylation signals than oncogenes and non-Census genes. (<bold>B</bold>) All Census genes classifiable as tumour suppressors (‘Tumour suppressors+;’ see Materials and methods) have stronger cleavage/polyadenylation signals compared to oncogenes and non-Census genes. (<bold>C</bold>) Tumour suppressors associated with ‘hallmarks of cancer’ have stronger cleavage/polyadenylation signals than ‘non-hallmark’ tumour suppressor genes.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99040-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Reduced tendency for copy number increases in genes with DOWN-paSNVs.</title><p>The graph illustrates the fraction of genes with copy number increases &gt;3 in at least one cancer sample. Notably, copy number increases are significantly less frequent in cancer genes affected by DOWN-paSNVs compared to their BG-paSNV counterparts. The lack of statistical significance in the comparison between tumour suppressors with DOWN-paSNVs and BG-paSNV genes is probably due to the limited number of copy number variation (CNV) events in the former group.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99040-fig4-figsupp3-v1.tif"/></fig></fig-group><p>Of note, our analysis of wild-type sequences showed that tumour suppressor 3’UTRs are characterized by stronger cleavage/polyadenylation signals compared to oncogenes and non-cancer genes (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A, B</xref>). Moreover, tumour suppressors associated with hallmarks of cancer (<xref ref-type="bibr" rid="bib12">Hanahan and Weinberg, 2011</xref>) in the Census dataset had stronger cleavage/polyadenylation signals than the rest of tumour suppressor genes (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>).</p><p>According to the classical two-hit hypothesis (<xref ref-type="bibr" rid="bib16">Knudson, 1971</xref>), both alleles of tumour suppressor genes may acquire distinct damaging mutations in cancer. With this in mind, we analysed the co-occurrence of paSNVs with damaging non-synonymous mutations from the PCAWG collection (non-syn. variants from the binarized gene-centric table in <xref ref-type="bibr" rid="bib6">Calabrese et al., 2020</xref>). DOWN-paSNV-containing tumour suppressors showed a markedly increased incidence of such additional somatic mutations in the same tumour compared to the BG-paSNV control (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Furthermore, the overall frequency of damaging non-synonymous mutations in tumour suppressors affected by DOWN-paSNVs in at least one sample was significantly higher than in the DOWN-paSNV-negative tumour suppressor group (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p><p>The analysis of allele copy number variation (CNV) showed that increased copy number was 4.1 times more common in the PCAWG data compared to allele loss. However, the incidence of copy number increase was substantially lower in the DOWN-paSNV group compared to the BG-paSNV control (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). This points to a negative selection against duplications of genes affected by DOWN-paSNVs in cancer.</p><p>Taken together, these data suggest that somatic mutations disrupting cleavage and polyadenylation can facilitate the inactivation of tumour suppressors in cancer.</p></sec><sec id="s2-3"><title>Somatic mutations in cleavage and polyadenylation signals can decrease the expression of tumour suppressor genes</title><p>Genetic inactivation of functional cleavage/polyadenylation sequences may negatively affect gene expression (see e.g. <xref ref-type="bibr" rid="bib13">Higgs et al., 1983</xref>). To explore this possibility, we turned to the colorectal adenocarcinoma subset of PCAWG, as it contained most of the DOWN-paSNVs in tumour suppressors and the corresponding gene expression information (<xref ref-type="bibr" rid="bib6">Calabrese et al., 2020</xref>). We shortlisted detectably expressed tumour suppressors that contained DOWN-paSNVs and no other damaging mutations in specific cancer samples, and were wild-type in other samples. Seven genes passing these filters were involved in various aspects of tumour biology, including cell survival and DNA repair (<italic>CASP9</italic>, <italic>NDRG1</italic>, and <italic>XPA</italic>), mTOR signalling (<italic>TSC1</italic>), and transcription and RNA processing (<italic>ETV6</italic>, <italic>ISY1,</italic> and <italic>SMAD2</italic>).</p><p>Plotting pairwise gene-specific expression differences for the aggregated tumour suppressor set, we observed a significant bias towards downregulation in the samples containing DOWN-paSNVs compared to the wild-type controls (<xref ref-type="fig" rid="fig5">Figure 5A</xref>; median downregulation of 1.25-fold). Remarkably, similar negative biases were detected for all seven individual genes, with median downregulation values ranging from 1.1- to 3.2-fold (<xref ref-type="fig" rid="fig5">Figure 5B</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Somatic cancer DOWN-paSNVs are sufficient to downregulate tumour suppressor genes.</title><p>(<bold>A, B</bold>) Gene-specific expression differences between DOWN-paSNV-containing and wild-type samples (ΔLog2 of copy number variation-normalized FPKM values; see Materials and Methods) reveal a consistently negative effect of DOWN-paSNV on tumour suppressor mRNA abundance in colorectal cancers. Box plots are shown for (<bold>A</bold>) an aggregated set of qualifying tumour suppressors and (<bold>B</bold>) individual genes from this set. Outliers are omitted for clarity. (<bold>C</bold>) Wild-type and mutated sequences of the <italic>XPA</italic> tumour suppressor gene cleavage/polyadenylation signal. The polyadenylation signal (PAS) hexamer is enclosed within a box. (<bold>D</bold>) Top, <italic>XPA</italic> cleavage site read-through minigenes and corresponding primers used for RT-qPCR analyses. Bottom, RT-qPCR data showing stronger read-through (weaker polyadenylation) in the mutant minigene. (<bold>E</bold>) Top, luciferase expression minigenes. Bottom, luciferase assay reveals that the cancer-specific PAS mutation dampens the expression of the reporter gene.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99040-fig5-v1.tif"/></fig><p>To validate the effect of DOWN-paSNVs on gene expression, we focused on a somatic mutation that disrupts the cleavage/polyadenylation signal in the tumour suppressor <italic>XPA</italic>. This gene has been shown to promote apoptosis in response to DNA damage, in addition to its role in nucleotide excision repair (<xref ref-type="bibr" rid="bib8">Deng et al., 2021</xref>). Moreover, downregulation of <italic>XPA</italic> has been associated with decreased patient survival in colorectal cancer (<xref ref-type="bibr" rid="bib10">Feng et al., 2018</xref>).</p><p>The <italic>XPA</italic> mutation identified by our bioinformatics analyses alters the canonical AATAAA PAS hexamer to GATAAA near the terminal CS and significantly reduces the APARENT2 score (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). To experimentally assess the effect of this mutation on the efficiency of pre-mRNA cleavage and polyadenylation, we prepared minigene constructs where the wild-type or mutant sequences were inserted upstream of a recombinant CS (<xref ref-type="fig" rid="fig5">Figure 5D</xref>).</p><p>We used the wild-type and mutant minigenes to transfect the human colorectal cancer cell line HCT-116. An RT-qPCR assay measuring the efficiency of cleavage/polyadenylation as a ratio between the CS-read-through and CS-upstream signals revealed a significant decrease in cleavage/polyadenylation efficiency in response to the <italic>XPA</italic> DOWN-paSNV (<xref ref-type="fig" rid="fig5">Figure 5D</xref>).</p><p>To directly assess the effect of defective cleavage/polyadenylation on gene expression, the wild-type or the mutant 3’UTR sequences were inserted downstream of a luciferase reporter gene. Following the transfection of HCT-116 cells, we detected a significantly reduced production of luciferase protein from the mutant construct compared to the wild-type control (<xref ref-type="fig" rid="fig5">Figure 5E</xref>).</p><p>Thus, somatic mutations disrupting polyadenylation signals in tumour suppressor genes can reduce the abundance of functional mRNA transcripts.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We interrogated whole-genome mutation data using recently developed machine-learning approaches to systematically characterize the impact of SNVs on 3’UTR polyadenylation signals (PAS) in cancer. Our analyses confirm that germline SNVs disrupting PAS are likely deleterious, as they are subjected to strong negative selection in the normal population (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Intriguingly, we found that somatic mutations affecting such cis-elements in cancer are more prevalent, tend to occur near stronger CSs, and target more evolutionarily conserved PAS hexamers (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><p>Importantly, these cancer somatic SNVs disrupt PAS sequences in tumour suppressor genes with a similar enrichment pattern to well-known deleterious SNVs in protein-coding regions, such as nonsense mutations (<xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>). Additionally, wild-type tumour suppressors have stronger cleavage/polyadenylation signals than other groups of genes (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), pointing to the importance of the corresponding steps of pre-mRNA processing for their expression.</p><p>Consistent with the two-hit hypothesis (<xref ref-type="bibr" rid="bib16">Knudson, 1971</xref>), we found that tumour suppressors with disrupted cleavage/polyadenylation signals (i.e. containing DOWN-paSNVs) are more likely to acquire other damaging somatic mutations in the same tumour (<xref ref-type="fig" rid="fig4">Figure 4C, D</xref>). As long-read genomic sequencing data become increasingly available, it will be interesting to investigate whether these additional mutations occur in the same or in a different allele compared to the DOWN-paSNVs.</p><p>However, it is possible that DOWN-paSNVs can contribute to tumour progression even in the absence of other mutations. Indeed, tumour suppressors containing only DOWN-paSNVs are consistently expressed at lower levels compared to their wild-type counterparts (<xref ref-type="fig" rid="fig5">Figure 5A, B</xref>). Moreover, it is currently thought that partial inactivation of many tumour suppressors can be sufficient to promote tumorigenesis (<xref ref-type="bibr" rid="bib3">Berger et al., 2011</xref>; <xref ref-type="bibr" rid="bib23">Park et al., 2021</xref>).</p><p>Using the tumour suppressor gene <italic>XPA</italic> as an example, we directly show that a cancer-specific single-nucleotide mutation disrupting the PAS hexamer is sufficient to block pre-mRNA cleavage/polyadenylation and dampen the expression of mature mRNA (<xref ref-type="fig" rid="fig5">Figure 5C, E</xref>). These results support our bioinformatics analyses and argue that SNVs targeting polyadenylation signals can have a profound effect on gene expression in cancer. Our data are also consistent with previous reports showing similar gene expression effects of PAS-specific germline SNVs (<xref ref-type="bibr" rid="bib13">Higgs et al., 1983</xref>; <xref ref-type="bibr" rid="bib2">Bennett et al., 2001</xref>).</p><p>It is expected that mutation of cleavage/polyadenylation signals should lead to the appearance of abnormal read-through transcripts that may be destabilized by either nuclear or cytoplasmic RNA quality control mechanisms (<xref ref-type="bibr" rid="bib5">Bresson and Tollervey, 2018</xref>). Alternatively, a decrease in cleavage/polyadenylation activity might dampen transcription initiation, as these two processes are known to be interconnected (<xref ref-type="bibr" rid="bib20">Mapendano et al., 2010</xref>). Differentiating between these possibilities will be an important next step in understanding the molecular mechanisms, which may link compromised cleavage/polyadenylation and gene expression defects in cancer. Furthermore, although we focused on annotated 3'UTR CSs in this work, similar analyses of SNVs occurring in other noncoding parts of mammalian genes (e.g. introns) might reveal an even wider impact of the loss and gain of PAS-like sequences in cancer.</p><p>In conclusion, our study reveals that the genetic inactivation of cleavage and polyadenylation in tumour suppressor genes constitutes a prevalent, yet previously overlooked category of somatic cancer mutations with driver properties. These findings emphasize the importance of pre-mRNA processing in the biology of cancer and underscore the need for improved functional annotation of single nucleotide variants in noncoding regions of the human genome.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>XPA</italic></td><td align="left" valign="bottom">Ensembl</td><td align="left" valign="bottom">ENSG00000136936</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">TOP10</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# C404003</td><td align="left" valign="bottom">Chemically competent cells</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Colorectal carcinoma, HCT-116</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CCL-247</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pEGFP-N3 (plasmid)</td><td align="left" valign="bottom">Clontech</td><td align="left" valign="bottom">Cat# 6080–1</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.addgene.org/vector-database/2493/">https://www.addgene.org/vector-database/2493/</ext-link></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pGL3-Control (plasmid)</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# U47296</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.addgene.org/212937/">https://www.addgene.org/212937/</ext-link></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pML651-WT (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Minigene</td><td align="left" valign="bottom">pEGFP-N3-based construct <break/>containing wild-type <italic>XPA</italic> 3’ region</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pML651-MUT (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Minigene</td><td align="left" valign="bottom">pEGFP-N3-based construct <break/>containing mutated <italic>XPA</italic> 3’ region</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pML663-WT (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Minigene</td><td align="left" valign="bottom">pGL3-based construct <break/>containing wild-type <italic>XPA</italic> 3’ region</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pML663-MUT (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Minigene</td><td align="left" valign="bottom">pGL3-based construct <break/>containing mutated <italic>XPA</italic> 3’ region</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">MLO4220</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">AACGCTAGCAAATAAAGGAAATTTAGATTGGTCCT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">MLO4221</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">ATCGGTCGACTCAACAATCAGATAGTCAACCATGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">MLO4159</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GCCCTAATAGCAGAGATAAACATTGAGTTG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">MLO4160</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CAACTCAATGTTTATCTCTGCTATTAGGGC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">MLO944</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GGCCGCGACTCTAGATCATAA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">MLO358</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GTAACCATTATAAGCTGCAATAAACAAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">MLO775</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">AGAACGGCATCAAGGTGAAC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">MLO776</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TGCTCAGGTAGTGGTTGTCG</named-content></td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">jetPRIME transfection reagent</td><td align="left" valign="bottom">Polyplus</td><td align="left" valign="bottom">Cat# 101000015</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Dual-Glo Luciferase Assay System</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# E2920</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">APARENT2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib19">Linder et al., 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/johli/aparent-resnet">https://github.com/johli/aparent-resnet</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DIGDriver</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib27">Sherman et al., 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/maxwellsh/DIGDriver">https://github.com/maxwellsh/DIGDriver</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">cluster Profiler</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Wu et al., 2021</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016884">SCR_016884</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://bioconductor.org/packages/release/bioc/html/clusterProfiler.html">http://bioconductor.org/packages/release/bioc/html/clusterProfiler.html</ext-link></td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Source data sets</title><p>Pre-mRNA CS positions and the corresponding metadata were obtained from the PolyA_DB3 database (<xref ref-type="bibr" rid="bib34">Wang et al., 2018</xref>) (release 3.2 <ext-link ext-link-type="uri" xlink:href="https://exon.apps.wistar.org/PolyA_DB/">https://exon.apps.wistar.org/PolyA_DB/</ext-link>). The phase-3 1000 genomes vcf files were downloaded from the International Genome Sample Resource (<ext-link ext-link-type="uri" xlink:href="https://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/release/">https://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/release/</ext-link>). Cancer somatic SNVs and indels from whole-genome sequencing of 2583 unique tumours (PCAWG) were downloaded from the International Cancer Genome Consortium (ICGC) data portal (<ext-link ext-link-type="uri" xlink:href="https://dcc.icgc.org/">https://dcc.icgc.org/</ext-link>) and the database of Genotypes and Phenotypes (dbGaP) (project code: phs000178). Only bona fide SNVs that differed from the reference genome at a single-nucleotide position were included in the analysis. The v97 release of the Cancer Gene Census was downloaded from <ext-link ext-link-type="uri" xlink:href="https://cancer.sanger.ac.uk/cosmic/download">https://cancer.sanger.ac.uk/cosmic/download</ext-link>.</p></sec><sec id="s4-2"><title>Data processing</title><p>CSs located in 3’UTRs according to PolyA_DB3 were extended by 102 nt on both sides to generate 205-nt intervals. All SNVs from the 1000 genomes and the PCAWG datasets mapping to these intervals were kept for further analyses (paSNVs). FASTA files corresponding to wild-type and mutant 205-nt intervals were analysed by the APARENT2 (<xref ref-type="bibr" rid="bib19">Linder et al., 2022</xref>). For each variant, we estimated the log odds ratio (LOR) of mutant (mut) variant isoform abundance with respect to the wild-type (wt) abundance (abundance was calculated by summing all cleavage probabilities mapping to 205-nt interval) as follows:<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>L</mml:mi><mml:mi>O</mml:mi><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>m</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>w</mml:mi><mml:mi>t</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>w</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>Incidence of PAS hexamers was quantified using the vcountPattern function from the Biostrings R/Bioconductor package (doi:10.18129/B9.bioc.Biostrings). Evolutionary conservation was calculated for either exact SNV positions or 15-nt SNV-centred windows using the GenomicScores (<xref ref-type="bibr" rid="bib25">Puigdevall and Castelo, 2018</xref>) and the phastCons100way.UCSC.hg19 (<xref ref-type="bibr" rid="bib30">Siepel et al., 2005</xref>) R/Bioconductor packages. Only unique SNV entries were kept for further analysis. In cases where a single SNV was located near more than one distinct CS, the strongest effect on cleavage/polyadenylation was used for further analyses. GO terms enrichment was analysed using the ClusterProfiler R/Bioconductor package (<xref ref-type="bibr" rid="bib36">Wu et al., 2021</xref>).</p><p>To analyse changes in polyadenylation scores of all mutations affecting AWTAAA sequences in 3’UTRs in <xref ref-type="fig" rid="fig2">Figure 2B</xref>, APARENT2 scores were calculated for all SNV-centred 205-nt intervals from both datasets located within canonical UCSC 3’UTRs. SNVs disrupting AWTAAA sequence with LOR≤–1 within 100-nt intervals centred around polyA_DB3 CSs were considered ‘annotated’.</p></sec><sec id="s4-3"><title>Cancer Census gene enrichment</title><p>Enrichment of different types of SNVs in Cancer Census genes was calculated using a two-tailed Fisher’s exact test. Somatic SNVs in protein-coding sequences were classified as ‘Nonsense,’ ‘Missense,’ or ‘Synonymous’ based on the information provided in PCAWG maf files (‘Variant_Classification’ column). Tumour suppressors were defined as genes labelled as ‘TSG’ but not ‘Oncogene’ in the Census dataset. A similar stringent approach was used to define oncogenes. Genes annotated as both ‘Tumour suppressors’ and ‘Oncogenes’ were excluded (most analyses), analysed as ‘Both’ (<xref ref-type="fig" rid="fig3">Figure 3A</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), or combined with tumour suppressors to form the extended ‘Tumour suppressor+’ group (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>).</p></sec><sec id="s4-4"><title>DigDriver enrichment analysis</title><p>We used the ‘Analyzing new mutation sets’ mode of DigDriver to process different functional categories of somatic SNVs. Functional annotation was taken from DigPreprocess.py annotMutationFile output files. Enrichment/excess of mutations of the Census cancer gene category was calculated as:<disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mfrac><mml:mrow><mml:mo>∑</mml:mo><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>m</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>∑</mml:mo><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mi>p</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>m</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:mo>∑</mml:mo><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>m</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mo>∑</mml:mo><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mi>p</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>m</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:mfrac></mml:mfrac></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>To calculate the 95% confidence interval (CI) of this enrichment, we performed bootstrap resampling of tumour suppressors, oncogenes and non-cancer genes in each mutation class for 1000 iterations. In each iteration, the enrichment/excess of mutations was calculated as described above. The 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles of the resampled distribution were used as the 95% confidence interval boundaries.</p></sec><sec id="s4-5"><title>Gene expression analysis</title><p>To analyse the possible effect of DOWN-paSNVs on transcript abundance, we selected tumour suppressor genes from the published colorectal adenocarcinoma study <xref ref-type="bibr" rid="bib6">Calabrese et al., 2020</xref>, which contained DOWN-paSNVs and no other damaging SNVs (i.e. Non-syn. variants from the binarized gene-centric table in <xref ref-type="bibr" rid="bib6">Calabrese et al., 2020</xref>) in some samples, and no mutations in other samples. We normalized the available gene expression data (FPKM) to account for gene copy number variation and log<sub>2</sub>-tranformed them to obtain Log2(nFPKM) values. Gene-specific Log2(nFPKM) values for the wild-type samples were then subtracted from corresponding Log2(nFPKM) values for the DOWN-paSNVs samples to obtain distributions of gene expression differences (ΔLog2(nFPKM)). A one-tailed Wilcoxon signed-rank test was used to analyse the significance of a negative shift of ΔLog2(nFPKM) distributions compared to 0.</p></sec><sec id="s4-6"><title>DNA constructs</title><p>All plasmids were propagated in the TOP10 <italic>E. coli</italic> strain (Thermo Fisher Scientific, cat# C404003). To generate read-through <italic>XPA</italic> minigenes (pML651-WT and pML651-MUT), a 431-nt gBlock fragment (Integrated DNA Technologies) encoding the human <italic>XPA</italic> 3’UTR in its natural context (chr9:100436867–100437297; GRCh37/hg19) and either the wild-type or mutated PAS were cloned into the pEGFP-N3 plasmid (Clontech) at the BsrGI and NotI sites. To generate luciferase reporter plasmids (pML663-WT and pML663-MUT), the entire <italic>XPA</italic> 3’UTR (chr9: 100437071–100437680; GRCh37/hg19) was amplified from HCT-116 genomic DNA using KAPA HiFi DNA polymerase HotStart ReadyMix (Roche, cat# KK2601) with MLO4220 (5'-<named-content content-type="sequence">AACGCTAGCAAATAAAGGAAATTTAGATTGGTCCT</named-content>-3') and MLO4221 (5'-<named-content content-type="sequence">ATCGGTCGACTCAACAATCAGATAGTCAACCATGA</named-content>-3') primers. The PCR product was gel-purified and cloned into the pGL3-Control plasmid (Promega, cat# U47296) at the XbaI and SalI sites. The cancer-specific PAS mutation was introduced using a modified Quikchange site-directed mutagenesis protocol, using the KAPA HiFi DNA polymerase HotStart ReadyMix (Roche, cat# KK2601) with MLO4159 (5'-<named-content content-type="sequence">GCCCTAATAGCAGAGATAAACATTGAGTTG</named-content>-3') and MLO4160 (5'-<named-content content-type="sequence">CAACTCAATGTTTATCTCTGCTATTAGGGC</named-content>-3') primers. All constructs were verified by Sanger sequencing. Plasmid maps are available on request.</p></sec><sec id="s4-7"><title>Minigenes experiments</title><p>HCT-116 cells were purchased from ATCC (Cat# CCL-247), confirmed to have characteristic morphology using light microscopy (<ext-link ext-link-type="uri" xlink:href="https://www.atcc.org/products/ccl-247#detailed-product-images">https://www.atcc.org/products/ccl-247#detailed-product-images</ext-link>), and tested negative for mycoplasma contamination using a LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich, cat# MP0035). Cells were cultured in a humidified incubator at 37 °C, 5% CO2, in DMEM containing 4.5 g/L glucose, GlutaMAX and 110 mg/L sodium pyruvate (Thermo Fisher Scientific, cat# 11360070) supplemented with 10% FBS (Hyclone, cat# SV30160.03) and 100 units/ml PenStrep (Thermo Fisher Scientific, cat# 15140122). For passaging, cells were washed with 1x PBS and dissociated in 0.05% Trypsin-EDTA (Thermo Fisher Scientific, cat# 15400054) for 10 min at 37 °C.</p><p>For read-through minigene transfection experiments, cells were typically seeded overnight in 1 mL of culture medium at 1–2×10<sup>5</sup> per well of a 12-well plate. Next morning, 1 μg of plasmid DNA was mixed with 2.5 μl of jetPRIME transfection reagent (Polyplus, cat# 101000015) in 150 μl of jetPRIME transfection buffer, incubated for 10 min at RT and added drop-wise to the cells. Total RNAs were extracted from cells 24 hr post-transfection using TRIzol (Thermo Fisher Scientific, cat#15596026) with an additional acidic phenol-chloroform (1:1) extraction step. The aqueous phase was precipitated with an equal volume of isopropanol, washed with 70% ethanol, and dissolved in 80 µl of nuclease-free water (Thermo Fisher Scientific, cat# AM9939). RNA samples were then treated with 4–6 units of Turbo DNase (Thermo Fisher Scientific, cat# AM2238) at 37 °C for 30 min to remove the bulk of plasmid DNA contamination, extracted with an equal volume of acidic phenol-chloroform (1:1), precipitated with 3 vol of 100% ethanol and 0.1 vol of 3 M sodium acetate (pH 5.2), washed with 70% ethanol and rehydrated in nuclease-free water. To remove any remaining traces of DNA, the RNA samples were additionally pre-treated with two units of RQ1-DNAse (Promega, cat# M6101) per 1 µg of RNA at 37 °C for 30 min. RQ1-DNAse was inactivated by adding the Stop Solution as recommended and the RNAs were immediately reverse-transcribed using SuperScript IV (Thermo Fisher Scientific, cat# 18090050) and random decamer (N10) primers at 50 °C for 30 min. cDNA samples were analysed by qPCR using a Light Cycler96 Real-Time PCR System (Roche) and qPCR BIO SyGreen Master Mix (PCR Biosystems, cat# PB20.11–51). The RT-qPCR signals downstream of the <italic>XPA</italic> cleavage site (MLO944, 5'-<named-content content-type="sequence">GGCCGCGACTCTAGATCATAA</named-content>-3' and MLO358, 5'-<named-content content-type="sequence">GTAACCATTATAAGCTGCAATAAACAAG</named-content>-3') were normalized to those obtained using upstream primers (MLO775, 5'-<named-content content-type="sequence">AGAACGGCATCAAGGTGAAC</named-content>-3' and MLO776, 5'-<named-content content-type="sequence">TGCTCAGGTAGTGGTTGTCG</named-content>-3').</p><p>For luciferase minigene transfection experiments, cells were typically seeded overnight in 100 μl of culture medium at 5×10<sup>3</sup> per well of a 96-well plate. Next morning, 70 ng of a firefly luciferase reporter construct containing <italic>XPA</italic> sequences and 30 ng of the <italic>Renilla</italic> luciferase control (pRL-TK; Promega) were mixed with 0.2 μl of jetPRIME transfection reagent in 10 μl of jetPRIME transfection buffer, incubated for 10 min at RT and added drop-wise to the cells. Following a 24 hr incubation, transfected cells were analysed using a Dual-Glo Luciferase Assay System (Promega, cat# E2920) as recommended by the manufacturer. Luminescence was measured using a Berthold Mithras LB940 plate reader.</p></sec><sec id="s4-8"><title>Statistics</title><p>Unless stated otherwise, all statistical procedures were performed in R. Data were averaged from at least three biological replicates and shown as box plots, with box bounds representing the first and the third quartiles and whiskers extending from the first and the third quartile to the lowest and highest data points or, if there are outliers, 1.5x of the interquartile range. Data obtained from RT-qPCR and luciferase assays were compared using the two-tailed Student’s t-test assuming unequal variances. Genome-wide data were analysed using the Wilcoxon rank sum test or Fisher’s exact test (two-tailed if not stated otherwise). Specific tests used and the p-values obtained are indicated in the figures and/or figure legends.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Software, Formal analysis, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Cancer somatic DOWN-paSNVs.</title><p>This table lists somatic DOWN-paSNVs predicted to reduce cleavage and polyadenylation efficiency across various Pan-Cancer Analysis of Whole Genomes (PCAWG) samples. For more information, please refer to the Description tab.</p></caption><media xlink:href="elife-99040-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-99040-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Maria Andrianova, Yegor Bazykin, Tim Hubbard, and Snezhka Oliferenko for helpful discussions. The results presented here are based in part on data generated by The Cancer Genome Atlas managed by the NCI and NHGRI (<ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/ccg/research/genome-sequencing/tcga">https://www.cancer.gov/ccg/research/genome-sequencing/tcga</ext-link>). This work was supported by the Biotechnology and Biological Sciences Research Council (grants BB/V006258/1 and BB/R001049/1 to EVM).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaudoing</surname><given-names>E</given-names></name><name><surname>Freier</surname><given-names>S</given-names></name><name><surname>Wyatt</surname><given-names>JR</given-names></name><name><surname>Claverie</surname><given-names>JM</given-names></name><name><surname>Gautheret</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Patterns of variant polyadenylation signal usage in human genes</article-title><source>Genome Research</source><volume>10</volume><fpage>1001</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1101/gr.10.7.1001</pub-id><pub-id pub-id-type="pmid">10899149</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>CL</given-names></name><name><surname>Brunkow</surname><given-names>ME</given-names></name><name><surname>Ramsdell</surname><given-names>F</given-names></name><name><surname>O’Briant</surname><given-names>KC</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Fuleihan</surname><given-names>RL</given-names></name><name><surname>Shigeoka</surname><given-names>AO</given-names></name><name><surname>Ochs</surname><given-names>HD</given-names></name><name><surname>Chance</surname><given-names>PF</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA--&gt;AAUGAA) leads to the IPEX syndrome</article-title><source>Immunogenetics</source><volume>53</volume><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1007/s002510100358</pub-id><pub-id pub-id-type="pmid">11685453</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>AH</given-names></name><name><surname>Knudson</surname><given-names>AG</given-names></name><name><surname>Pandolfi</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A continuum model for tumour suppression</article-title><source>Nature</source><volume>476</volume><fpage>163</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1038/nature10275</pub-id><pub-id pub-id-type="pmid">21833082</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogard</surname><given-names>N</given-names></name><name><surname>Linder</surname><given-names>J</given-names></name><name><surname>Rosenberg</surname><given-names>AB</given-names></name><name><surname>Seelig</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A deep neural network for predicting and engineering alternative polyadenylation</article-title><source>Cell</source><volume>178</volume><fpage>91</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.04.046</pub-id><pub-id pub-id-type="pmid">31178116</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bresson</surname><given-names>S</given-names></name><name><surname>Tollervey</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Surveillance-ready transcription: nuclear RNA decay as a default fate</article-title><source>Open Biology</source><volume>8</volume><elocation-id>170270</elocation-id><pub-id pub-id-type="doi">10.1098/rsob.170270</pub-id><pub-id pub-id-type="pmid">29563193</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>C</given-names></name><name><surname>Davidson</surname><given-names>NR</given-names></name><name><surname>Demircioğlu</surname><given-names>D</given-names></name><name><surname>Fonseca</surname><given-names>NA</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Kahles</surname><given-names>A</given-names></name><name><surname>Lehmann</surname><given-names>K-V</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Shiraishi</surname><given-names>Y</given-names></name><name><surname>Soulette</surname><given-names>CM</given-names></name><name><surname>Urban</surname><given-names>L</given-names></name><name><surname>Greger</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Perry</surname><given-names>MD</given-names></name><name><surname>Xiang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Bailey</surname><given-names>P</given-names></name><name><surname>Erkek</surname><given-names>S</given-names></name><name><surname>Hoadley</surname><given-names>KA</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Huska</surname><given-names>MR</given-names></name><name><surname>Kilpinen</surname><given-names>H</given-names></name><name><surname>Korbel</surname><given-names>JO</given-names></name><name><surname>Marin</surname><given-names>MG</given-names></name><name><surname>Markowski</surname><given-names>J</given-names></name><name><surname>Nandi</surname><given-names>T</given-names></name><name><surname>Pan-Hammarström</surname><given-names>Q</given-names></name><name><surname>Pedamallu</surname><given-names>CS</given-names></name><name><surname>Siebert</surname><given-names>R</given-names></name><name><surname>Stark</surname><given-names>SG</given-names></name><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Tan</surname><given-names>P</given-names></name><name><surname>Waszak</surname><given-names>SM</given-names></name><name><surname>Yung</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Awadalla</surname><given-names>P</given-names></name><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Ouellette</surname><given-names>BFF</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Brazma</surname><given-names>A</given-names></name><name><surname>Brooks</surname><given-names>AN</given-names></name><name><surname>Göke</surname><given-names>J</given-names></name><name><surname>Rätsch</surname><given-names>G</given-names></name><name><surname>Schwarz</surname><given-names>RF</given-names></name><name><surname>Stegle</surname><given-names>O</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><collab>PCAWG Transcriptome Core Group</collab><collab>PCAWG Transcriptome Working Group</collab><collab>PCAWG Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Genomic basis for RNA alterations in cancer</article-title><source>Nature</source><volume>578</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1970-0</pub-id><pub-id pub-id-type="pmid">32025019</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>DC</given-names></name><name><surname>Oh</surname><given-names>C</given-names></name><name><surname>Jayasinghe</surname><given-names>RG</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Yoon</surname><given-names>CJ</given-names></name><name><surname>Wyczalkowski</surname><given-names>MA</given-names></name><name><surname>Bailey</surname><given-names>MH</given-names></name><name><surname>Tsou</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Malone</surname><given-names>A</given-names></name><name><surname>Reynolds</surname><given-names>S</given-names></name><name><surname>Shmulevich</surname><given-names>I</given-names></name><name><surname>Wendl</surname><given-names>MC</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Discovery of driver non-coding splice-site-creating mutations in cancer</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>5573</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19307-6</pub-id><pub-id pub-id-type="pmid">33149122</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>QS</given-names></name><name><surname>Huang</surname><given-names>WF</given-names></name><name><surname>Dai</surname><given-names>JW</given-names></name><name><surname>Wu</surname><given-names>ZJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>XPA serves as an autophagy and apoptosis inducer by suppressing hepatocellular carcinoma in a PI3K/Akt/mTOR dependent manner</article-title><source>Journal of Gastrointestinal Oncology</source><volume>12</volume><fpage>1797</fpage><lpage>1810</lpage><pub-id pub-id-type="doi">10.21037/jgo-21-310</pub-id><pub-id pub-id-type="pmid">34532129</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fairley</surname><given-names>S</given-names></name><name><surname>Lowy-Gallego</surname><given-names>E</given-names></name><name><surname>Perry</surname><given-names>E</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The International Genome Sample Resource (IGSR) collection of open human genomic variation resources</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>D941</fpage><lpage>D947</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz836</pub-id><pub-id pub-id-type="pmid">31584097</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Gou</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>DNA repair protein XPA is differentially expressed in colorectal cancer and predicts better prognosis</article-title><source>Cancer Medicine</source><volume>7</volume><fpage>2339</fpage><lpage>2349</lpage><pub-id pub-id-type="doi">10.1002/cam4.1480</pub-id><pub-id pub-id-type="pmid">29675892</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Findlay</surname><given-names>SD</given-names></name><name><surname>Romo</surname><given-names>L</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Quantifying negative selection in human 3’ UTRs uncovers constrained targets of RNA-binding proteins</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2022.11.30.518628</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgs</surname><given-names>DR</given-names></name><name><surname>Goodbourn</surname><given-names>SE</given-names></name><name><surname>Lamb</surname><given-names>J</given-names></name><name><surname>Clegg</surname><given-names>JB</given-names></name><name><surname>Weatherall</surname><given-names>DJ</given-names></name><name><surname>Proudfoot</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Alpha-thalassaemia caused by a polyadenylation signal mutation</article-title><source>Nature</source><volume>306</volume><fpage>398</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1038/306398a0</pub-id><pub-id pub-id-type="pmid">6646217</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Pan-cancer analysis of whole genomes</article-title><source>Nature</source><volume>578</volume><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1969-6</pub-id><pub-id pub-id-type="pmid">32025007</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kainov</surname><given-names>YA</given-names></name><name><surname>Aushev</surname><given-names>VN</given-names></name><name><surname>Naumenko</surname><given-names>SA</given-names></name><name><surname>Tchevkina</surname><given-names>EM</given-names></name><name><surname>Bazykin</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Complex selection on human polyadenylation signals revealed by polymorphism and divergence data</article-title><source>Genome Biology and Evolution</source><volume>8</volume><fpage>1971</fpage><lpage>1979</lpage><pub-id pub-id-type="doi">10.1093/gbe/evw137</pub-id><pub-id pub-id-type="pmid">27324920</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudson</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="1971">1971</year><article-title>Mutation and cancer: statistical study of retinoblastoma</article-title><source>PNAS</source><volume>68</volume><fpage>820</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1073/pnas.68.4.820</pub-id><pub-id pub-id-type="pmid">5279523</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Tisdale</surname><given-names>S</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Leslie</surname><given-names>CS</given-names></name><name><surname>Mayr</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia</article-title><source>Nature</source><volume>561</volume><fpage>127</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0465-8</pub-id><pub-id pub-id-type="pmid">30150773</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Ning</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Geng</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Miao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Genetic variants that impact alternative polyadenylation in cancer represent candidate causal risk loci</article-title><source>Cancer Research</source><volume>83</volume><fpage>3650</fpage><lpage>3666</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-23-0251</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linder</surname><given-names>J</given-names></name><name><surname>Koplik</surname><given-names>SE</given-names></name><name><surname>Kundaje</surname><given-names>A</given-names></name><name><surname>Seelig</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Deciphering the impact of genetic variation on human polyadenylation using APARENT2</article-title><source>Genome Biology</source><volume>23</volume><elocation-id>232</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-022-02799-4</pub-id><pub-id pub-id-type="pmid">36335397</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mapendano</surname><given-names>CK</given-names></name><name><surname>Lykke-Andersen</surname><given-names>S</given-names></name><name><surname>Kjems</surname><given-names>J</given-names></name><name><surname>Bertrand</surname><given-names>E</given-names></name><name><surname>Jensen</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Crosstalk between mRNA 3’ end processing and transcription initiation</article-title><source>Molecular Cell</source><volume>40</volume><fpage>410</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.10.012</pub-id><pub-id pub-id-type="pmid">21070967</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayr</surname><given-names>C</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Widespread shortening of 3’UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells</article-title><source>Cell</source><volume>138</volume><fpage>673</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.06.016</pub-id><pub-id pub-id-type="pmid">19703394</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neve</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Louey</surname><given-names>A</given-names></name><name><surname>Furger</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cleavage and polyadenylation: Ending the message expands gene regulation</article-title><source>RNA Biology</source><volume>14</volume><fpage>865</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1080/15476286.2017.1306171</pub-id><pub-id pub-id-type="pmid">28453393</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Supek</surname><given-names>F</given-names></name><name><surname>Lehner</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Higher order genetic interactions switch cancer genes from two-hit to one-hit drivers</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>27242-3</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-27242-3</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proudfoot</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Poly(A) signals</article-title><source>Cell</source><volume>64</volume><fpage>671</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(91)90495-k</pub-id><pub-id pub-id-type="pmid">1671760</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puigdevall</surname><given-names>P</given-names></name><name><surname>Castelo</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>GenomicScores: seamless access to genomewide position-specific scores from R and Bioconductor</article-title><source>Bioinformatics</source><volume>34</volume><fpage>3208</fpage><lpage>3210</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty311</pub-id><pub-id pub-id-type="pmid">29718111</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rheinbay</surname><given-names>E</given-names></name><name><surname>Nielsen</surname><given-names>MM</given-names></name><name><surname>Abascal</surname><given-names>F</given-names></name><name><surname>Wala</surname><given-names>JA</given-names></name><name><surname>Shapira</surname><given-names>O</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Hornshøj</surname><given-names>H</given-names></name><name><surname>Hess</surname><given-names>JM</given-names></name><name><surname>Juul</surname><given-names>RI</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Feuerbach</surname><given-names>L</given-names></name><name><surname>Sabarinathan</surname><given-names>R</given-names></name><name><surname>Madsen</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Mularoni</surname><given-names>L</given-names></name><name><surname>Shuai</surname><given-names>S</given-names></name><name><surname>Lanzós</surname><given-names>A</given-names></name><name><surname>Herrmann</surname><given-names>C</given-names></name><name><surname>Maruvka</surname><given-names>YE</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Amin</surname><given-names>SB</given-names></name><name><surname>Bandopadhayay</surname><given-names>P</given-names></name><name><surname>Bertl</surname><given-names>J</given-names></name><name><surname>Boroevich</surname><given-names>KA</given-names></name><name><surname>Busanovich</surname><given-names>J</given-names></name><name><surname>Carlevaro-Fita</surname><given-names>J</given-names></name><name><surname>Chakravarty</surname><given-names>D</given-names></name><name><surname>Chan</surname><given-names>CWY</given-names></name><name><surname>Craft</surname><given-names>D</given-names></name><name><surname>Dhingra</surname><given-names>P</given-names></name><name><surname>Diamanti</surname><given-names>K</given-names></name><name><surname>Fonseca</surname><given-names>NA</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Hamilton</surname><given-names>MP</given-names></name><name><surname>Haradhvala</surname><given-names>NJ</given-names></name><name><surname>Hong</surname><given-names>C</given-names></name><name><surname>Isaev</surname><given-names>K</given-names></name><name><surname>Johnson</surname><given-names>TA</given-names></name><name><surname>Juul</surname><given-names>M</given-names></name><name><surname>Kahles</surname><given-names>A</given-names></name><name><surname>Kahraman</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Komorowski</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Lehmann</surname><given-names>K-V</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>EM</given-names></name><name><surname>Lochovsky</surname><given-names>L</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Pich</surname><given-names>O</given-names></name><name><surname>Roberts</surname><given-names>ND</given-names></name><name><surname>Saksena</surname><given-names>G</given-names></name><name><surname>Schumacher</surname><given-names>SE</given-names></name><name><surname>Sidiropoulos</surname><given-names>N</given-names></name><name><surname>Sieverling</surname><given-names>L</given-names></name><name><surname>Sinnott-Armstrong</surname><given-names>N</given-names></name><name><surname>Stewart</surname><given-names>C</given-names></name><name><surname>Tamborero</surname><given-names>D</given-names></name><name><surname>Tubio</surname><given-names>JMC</given-names></name><name><surname>Umer</surname><given-names>HM</given-names></name><name><surname>Uusküla-Reimand</surname><given-names>L</given-names></name><name><surname>Wadelius</surname><given-names>C</given-names></name><name><surname>Wadi</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C-Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Haber</surname><given-names>JE</given-names></name><name><surname>Hobolth</surname><given-names>A</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>von Mering</surname><given-names>C</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Stein</surname><given-names>LD</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Reimand</surname><given-names>J</given-names></name><name><surname>Gerstein</surname><given-names>M</given-names></name><name><surname>Khurana</surname><given-names>E</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>López-Bigas</surname><given-names>N</given-names></name><collab>PCAWG Drivers and Functional Interpretation Working Group</collab><collab>PCAWG Structural Variation Working Group</collab><name><surname>Weischenfeldt</surname><given-names>J</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Martincorena</surname><given-names>I</given-names></name><name><surname>Pedersen</surname><given-names>JS</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><collab>PCAWG Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Analyses of non-coding somatic drivers in 2,658 cancer whole genomes</article-title><source>Nature</source><volume>578</volume><fpage>102</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1965-x</pub-id><pub-id pub-id-type="pmid">32025015</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>MA</given-names></name><name><surname>Yaari</surname><given-names>AU</given-names></name><name><surname>Priebe</surname><given-names>O</given-names></name><name><surname>Dietlein</surname><given-names>F</given-names></name><name><surname>Loh</surname><given-names>PR</given-names></name><name><surname>Berger</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Genome-wide mapping of somatic mutation rates uncovers drivers of cancer</article-title><source>Nature Biotechnology</source><volume>40</volume><fpage>1634</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1038/s41587-022-01353-8</pub-id><pub-id pub-id-type="pmid">35726091</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Di Giammartino</surname><given-names>DC</given-names></name><name><surname>Taylor</surname><given-names>D</given-names></name><name><surname>Sarkeshik</surname><given-names>A</given-names></name><name><surname>Rice</surname><given-names>WJ</given-names></name><name><surname>Yates</surname><given-names>JR</given-names><suffix>III</suffix></name><name><surname>Frank</surname><given-names>J</given-names></name><name><surname>Manley</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Molecular architecture of the human pre-mRNA 3′ processing complex</article-title><source>Molecular Cell</source><volume>33</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2008.12.028</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shlien</surname><given-names>A</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Fuligni</surname><given-names>F</given-names></name><name><surname>Arnold</surname><given-names>R</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Dronov</surname><given-names>S</given-names></name><name><surname>Mamanova</surname><given-names>L</given-names></name><name><surname>Rosic</surname><given-names>A</given-names></name><name><surname>Ju</surname><given-names>YS</given-names></name><name><surname>Cooke</surname><given-names>SL</given-names></name><name><surname>Ramakrishna</surname><given-names>M</given-names></name><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Davies</surname><given-names>HR</given-names></name><name><surname>Tarpey</surname><given-names>PS</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>E</given-names></name><name><surname>Hardy</surname><given-names>C</given-names></name><collab>ICGC Breast Cancer Working Group, Oslo Breast Cancer Research Consortium</collab><name><surname>Barbashina</surname><given-names>V</given-names></name><name><surname>Aparicio</surname><given-names>SAJR</given-names></name><name><surname>Sauer</surname><given-names>T</given-names></name><name><surname>Garred</surname><given-names>Ø</given-names></name><name><surname>Vincent-Salomon</surname><given-names>A</given-names></name><name><surname>Mariani</surname><given-names>O</given-names></name><name><surname>Boyault</surname><given-names>S</given-names></name><name><surname>Fatima</surname><given-names>A</given-names></name><name><surname>Langerød</surname><given-names>A</given-names></name><name><surname>Borg</surname><given-names>Å</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Børresen-Dale</surname><given-names>A-L</given-names></name><name><surname>Polyak</surname><given-names>K</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Direct transcriptional consequences of somatic mutation in breast cancer</article-title><source>Cell Reports</source><volume>16</volume><fpage>2032</fpage><lpage>2046</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.07.028</pub-id><pub-id pub-id-type="pmid">27498871</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siepel</surname><given-names>A</given-names></name><name><surname>Bejerano</surname><given-names>G</given-names></name><name><surname>Pedersen</surname><given-names>JS</given-names></name><name><surname>Hinrichs</surname><given-names>AS</given-names></name><name><surname>Hou</surname><given-names>M</given-names></name><name><surname>Rosenbloom</surname><given-names>K</given-names></name><name><surname>Clawson</surname><given-names>H</given-names></name><name><surname>Spieth</surname><given-names>J</given-names></name><name><surname>Hillier</surname><given-names>LW</given-names></name><name><surname>Richards</surname><given-names>S</given-names></name><name><surname>Weinstock</surname><given-names>GM</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Kent</surname><given-names>WJ</given-names></name><name><surname>Miller</surname><given-names>W</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes</article-title><source>Genome Research</source><volume>15</volume><fpage>1034</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1101/gr.3715005</pub-id><pub-id pub-id-type="pmid">16024819</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stacey</surname><given-names>SN</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Jonasdottir</surname><given-names>A</given-names></name><name><surname>Masson</surname><given-names>G</given-names></name><name><surname>Gudmundsson</surname><given-names>J</given-names></name><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name><surname>Magnusson</surname><given-names>OT</given-names></name><name><surname>Gudjonsson</surname><given-names>SA</given-names></name><name><surname>Sigurgeirsson</surname><given-names>B</given-names></name><name><surname>Thorisdottir</surname><given-names>K</given-names></name><name><surname>Ragnarsson</surname><given-names>R</given-names></name><name><surname>Benediktsdottir</surname><given-names>KR</given-names></name><name><surname>Nexø</surname><given-names>BA</given-names></name><name><surname>Tjønneland</surname><given-names>A</given-names></name><name><surname>Overvad</surname><given-names>K</given-names></name><name><surname>Rudnai</surname><given-names>P</given-names></name><name><surname>Gurzau</surname><given-names>E</given-names></name><name><surname>Koppova</surname><given-names>K</given-names></name><name><surname>Hemminki</surname><given-names>K</given-names></name><name><surname>Corredera</surname><given-names>C</given-names></name><name><surname>Fuentelsaz</surname><given-names>V</given-names></name><name><surname>Grasa</surname><given-names>P</given-names></name><name><surname>Navarrete</surname><given-names>S</given-names></name><name><surname>Fuertes</surname><given-names>F</given-names></name><name><surname>García-Prats</surname><given-names>MD</given-names></name><name><surname>Sanambrosio</surname><given-names>E</given-names></name><name><surname>Panadero</surname><given-names>A</given-names></name><name><surname>De Juan</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>A</given-names></name><name><surname>Rivera</surname><given-names>F</given-names></name><name><surname>Planelles</surname><given-names>D</given-names></name><name><surname>Soriano</surname><given-names>V</given-names></name><name><surname>Requena</surname><given-names>C</given-names></name><name><surname>Aben</surname><given-names>KK</given-names></name><name><surname>van Rossum</surname><given-names>MM</given-names></name><name><surname>Cremers</surname><given-names>RGHM</given-names></name><name><surname>van Oort</surname><given-names>IM</given-names></name><name><surname>van Spronsen</surname><given-names>D-J</given-names></name><name><surname>Schalken</surname><given-names>JA</given-names></name><name><surname>Peters</surname><given-names>WHM</given-names></name><name><surname>Helfand</surname><given-names>BT</given-names></name><name><surname>Donovan</surname><given-names>JL</given-names></name><name><surname>Hamdy</surname><given-names>FC</given-names></name><name><surname>Badescu</surname><given-names>D</given-names></name><name><surname>Codreanu</surname><given-names>O</given-names></name><name><surname>Jinga</surname><given-names>M</given-names></name><name><surname>Csiki</surname><given-names>IE</given-names></name><name><surname>Constantinescu</surname><given-names>V</given-names></name><name><surname>Badea</surname><given-names>P</given-names></name><name><surname>Mates</surname><given-names>IN</given-names></name><name><surname>Dinu</surname><given-names>DE</given-names></name><name><surname>Constantin</surname><given-names>A</given-names></name><name><surname>Mates</surname><given-names>D</given-names></name><name><surname>Kristjansdottir</surname><given-names>S</given-names></name><name><surname>Agnarsson</surname><given-names>BA</given-names></name><name><surname>Jonsson</surname><given-names>E</given-names></name><name><surname>Barkardottir</surname><given-names>RB</given-names></name><name><surname>Einarsson</surname><given-names>GV</given-names></name><name><surname>Sigurdsson</surname><given-names>F</given-names></name><name><surname>Moller</surname><given-names>PH</given-names></name><name><surname>Stefansson</surname><given-names>T</given-names></name><name><surname>Valdimarsson</surname><given-names>T</given-names></name><name><surname>Johannsson</surname><given-names>OT</given-names></name><name><surname>Sigurdsson</surname><given-names>H</given-names></name><name><surname>Jonsson</surname><given-names>T</given-names></name><name><surname>Jonasson</surname><given-names>JG</given-names></name><name><surname>Tryggvadottir</surname><given-names>L</given-names></name><name><surname>Rice</surname><given-names>T</given-names></name><name><surname>Hansen</surname><given-names>HM</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Lachance</surname><given-names>DH</given-names></name><name><surname>O Neill</surname><given-names>BP</given-names></name><name><surname>Kosel</surname><given-names>ML</given-names></name><name><surname>Decker</surname><given-names>PA</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Johannsdottir</surname><given-names>H</given-names></name><name><surname>Helgadottir</surname><given-names>HT</given-names></name><name><surname>Sigurdsson</surname><given-names>A</given-names></name><name><surname>Steinthorsdottir</surname><given-names>V</given-names></name><name><surname>Lindblom</surname><given-names>A</given-names></name><collab>Swedish Low-risk Colorectal Cancer Study Group</collab><name><surname>Sandler</surname><given-names>RS</given-names></name><name><surname>Keku</surname><given-names>TO</given-names></name><name><surname>Banasik</surname><given-names>K</given-names></name><name><surname>Jørgensen</surname><given-names>T</given-names></name><name><surname>Witte</surname><given-names>DR</given-names></name><name><surname>Hansen</surname><given-names>T</given-names></name><name><surname>Pedersen</surname><given-names>O</given-names></name><name><surname>Jinga</surname><given-names>V</given-names></name><name><surname>Neal</surname><given-names>DE</given-names></name><name><surname>Catalona</surname><given-names>WJ</given-names></name><name><surname>Wrensch</surname><given-names>M</given-names></name><name><surname>Wiencke</surname><given-names>J</given-names></name><name><surname>Jenkins</surname><given-names>RB</given-names></name><name><surname>Nagore</surname><given-names>E</given-names></name><name><surname>Vogel</surname><given-names>U</given-names></name><name><surname>Kiemeney</surname><given-names>LA</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Mayordomo</surname><given-names>JI</given-names></name><name><surname>Olafsson</surname><given-names>JH</given-names></name><name><surname>Kong</surname><given-names>A</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Rafnar</surname><given-names>T</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A germline variant in the TP53 polyadenylation signal confers cancer susceptibility</article-title><source>Nature Genetics</source><volume>43</volume><fpage>1098</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1038/ng.926</pub-id><pub-id pub-id-type="pmid">21946351</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tate</surname><given-names>JG</given-names></name><name><surname>Bamford</surname><given-names>S</given-names></name><name><surname>Jubb</surname><given-names>HC</given-names></name><name><surname>Sondka</surname><given-names>Z</given-names></name><name><surname>Beare</surname><given-names>DM</given-names></name><name><surname>Bindal</surname><given-names>N</given-names></name><name><surname>Boutselakis</surname><given-names>H</given-names></name><name><surname>Cole</surname><given-names>CG</given-names></name><name><surname>Creatore</surname><given-names>C</given-names></name><name><surname>Dawson</surname><given-names>E</given-names></name><name><surname>Fish</surname><given-names>P</given-names></name><name><surname>Harsha</surname><given-names>B</given-names></name><name><surname>Hathaway</surname><given-names>C</given-names></name><name><surname>Jupe</surname><given-names>SC</given-names></name><name><surname>Kok</surname><given-names>CY</given-names></name><name><surname>Noble</surname><given-names>K</given-names></name><name><surname>Ponting</surname><given-names>L</given-names></name><name><surname>Ramshaw</surname><given-names>CC</given-names></name><name><surname>Rye</surname><given-names>CE</given-names></name><name><surname>Speedy</surname><given-names>HE</given-names></name><name><surname>Stefancsik</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>SL</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Forbes</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>COSMIC: the catalogue of somatic mutations in cancer</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D941</fpage><lpage>D947</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1015</pub-id><pub-id pub-id-type="pmid">30371878</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>B</given-names></name><name><surname>Manley</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Alternative polyadenylation of mRNA precursors</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>18</volume><fpage>18</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/nrm.2016.116</pub-id><pub-id pub-id-type="pmid">27677860</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Nambiar</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Tian</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>PolyA_DB 3 catalogs cleavage and polyadenylation sites identified by deep sequencing in multiple genomes</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D315</fpage><lpage>D319</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1000</pub-id><pub-id pub-id-type="pmid">29069441</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiestner</surname><given-names>A</given-names></name><name><surname>Tehrani</surname><given-names>M</given-names></name><name><surname>Chiorazzi</surname><given-names>M</given-names></name><name><surname>Wright</surname><given-names>G</given-names></name><name><surname>Gibellini</surname><given-names>F</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Rosenwald</surname><given-names>A</given-names></name><name><surname>Muller-Hermelink</surname><given-names>HK</given-names></name><name><surname>Ott</surname><given-names>G</given-names></name><name><surname>Chan</surname><given-names>WC</given-names></name><name><surname>Greiner</surname><given-names>TC</given-names></name><name><surname>Weisenburger</surname><given-names>DD</given-names></name><name><surname>Vose</surname><given-names>J</given-names></name><name><surname>Armitage</surname><given-names>JO</given-names></name><name><surname>Gascoyne</surname><given-names>RD</given-names></name><name><surname>Connors</surname><given-names>JM</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Montserrat</surname><given-names>E</given-names></name><name><surname>Bosch</surname><given-names>F</given-names></name><name><surname>Smeland</surname><given-names>EB</given-names></name><name><surname>Kvaloy</surname><given-names>S</given-names></name><name><surname>Holte</surname><given-names>H</given-names></name><name><surname>Delabie</surname><given-names>J</given-names></name><name><surname>Fisher</surname><given-names>RI</given-names></name><name><surname>Grogan</surname><given-names>TM</given-names></name><name><surname>Miller</surname><given-names>TP</given-names></name><name><surname>Wilson</surname><given-names>WH</given-names></name><name><surname>Jaffe</surname><given-names>ES</given-names></name><name><surname>Staudt</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival</article-title><source>Blood</source><volume>109</volume><fpage>4599</fpage><lpage>4606</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-08-039859</pub-id><pub-id pub-id-type="pmid">17299095</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Bo</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>clusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title><source>Innovation</source><volume>2</volume><elocation-id>100141</elocation-id><pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id><pub-id pub-id-type="pmid">34557778</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Wei</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Ni</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Comprehensive characterization of somatic variants associated with intronic polyadenylation in human cancers</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>10369</fpage><lpage>10381</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab772</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99040.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Murim</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Seoul National University</institution><country>Republic of Korea</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study substantially advances our understanding of noncoding somatic mutations by identifying a novel class of mutations that affect 3'UTR polyadenylation signals enriched in tumor suppressor genes in cancer. The evidence supporting the conclusions is <bold>convincing</bold>, with rigorous statistical analyses. The work will be of broad interest to cancer researchers.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99040.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Kainov et al investigated the prevalence of mutations in 3'UTR that affect gene expression in cancer to identify noncoding cancer drivers.</p><p>The authors used data from normal controls (1000 genome data) and compared it to cancer data (PCAWG). They found that in cancer 3'UTR mutations had a stronger effect on cleavage than the normal population. These mutations are negatively selected in the normal population and positively selected in cancers. The authors used PCAWG data set to identify such mutations and found that the mutations that lead to a reduction of gene expression are enriched in tumor suppressor genes and those that are increased in gene expression are enriched for oncogenes. 3'UTR mutations that reduce gene expression or occur in TSGs co-occur with non-synonymous mutations. The authors then validate the effect of 3'UTR mutations experimentally using a luciferase reporter assay. These data identify a novel class of noncoding driver genes with mutations in 3'UTR that impact polyadenylation and thus gene expression.</p><p>This is an elegant study with fundamental insight into identifying cancer driver genes. The conclusions of this paper are mostly well supported by data, but some aspects of data analysis need to be extended.</p><p>Comments on revisions:</p><p>The authors addressed most of my comments.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99040.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kainov</surname><given-names>Yaroslav</given-names></name><role specific-use="author">Author</role><aff><institution>King&amp;apos;s College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Hamid</surname><given-names>Fursham</given-names></name><role specific-use="author">Author</role><aff><institution>Kings College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Makeyev</surname><given-names>Eugene V</given-names></name><role specific-use="author">Author</role><aff><institution>King&amp;apos;s College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Kainov et al investigated the prevalence of mutations in 3'UTR that affect gene expression in cancer to identify noncoding cancer drivers.</p><p>The authors used data from normal controls (1000 genome data) and compared it to cancer data (PCAWG). They found that in cancer 3'UTR mutations had a stronger effect on cleavage than the normal population. These mutations are negatively selected in the normal population and positively selected in cancers. The authors used PCAWG data set to identify such mutations and found that the mutations that lead to a reduction of gene expression are enriched in tumor suppressor genes and those that are increased in gene expression are enriched for oncogenes. 3'UTR mutations that reduce gene expression or occur in TSGs cooccur with non-synonymous mutations. The authors then validate the effect of 3'UTR mutations experimentally using a luciferase reporter assay. These data identify a novel class of noncoding driver genes with mutations in 3'UTR that impact polyadenylation and thus gene expression.</p><p>This is an elegant study with fundamental insight into identifying cancer driver genes. The conclusions of this paper are mostly well supported by data, but some aspects of data analysis need to be extended.</p></disp-quote><p>We thank the reviewer for the positive assessment of our work and constructive comments.</p><disp-quote content-type="editor-comment"><p>(1) It would be important for the authors to show if the findings of this study hold for metastatic cancers since most deaths occur due to metastasis and tumor heterogeneity changes when cancer progresses to metastasis. The authors should use the Hartwig data and show if metastatic cancers are enriched for 3'UTR mutations.</p></disp-quote><p>This is a good suggestion, but we believe that the proposed analysis would have a significantly stronger impact in the context of a separate study focused specifically on longitudinal changes in the somatic mutation landscape as cancer progresses from primary tumours to metastases. Conducting such a study would require obtaining permissions to use relevant controlled datasets and, ideally, collaborating with oncologists to generate additional genome and transcriptome sequencing data. As such, this level of analysis would go beyond the current scope of our work.</p><disp-quote content-type="editor-comment"><p>(2) Figure 2 should show the distribution of 3'UTR mutations by cancer type especially since authors go on to use colorectal cancer only for validations. It would be helpful to bring Figures S3A and S3C to this panel since these findings make the connections to cancer biology. Are any molecular functions enriched in addition to biological processes? Are kinases, phosphatases, etc more or less affected by 3'UTR mutations?</p></disp-quote><p>As suggested, we have added a pie chart showing the distribution of 3’UTR mutations by cancer type (new Fig. 2E). Notably, nearly a half of the mutations in our dataset was of colorectal adenocarcinoma origin, justifying the focus on this type of cancer in our subsequent validation analyses.</p><p>To strengthen the connections to cancer biology, we moved Fig. S3A and S3C to the main text. It was more logical to integrate these panels into Fig. 3 rather than Fig. 2. We also analysed molecular function enrichment in Fig. 3E. Consistent with the biological process enrichment (now shown in Fig. 3D), this revealed an enrichment of proteins interacting with the ubiquitination pathway, including tumour suppressors <italic>SMAD2</italic>, <italic>APC</italic> and <italic>AXIN1</italic>.</p><disp-quote content-type="editor-comment"><p>(3) Figure 3 looks at the co-occurrence of 3'UTR mutations with non-synonymous mutations but what about copy number change? You would expect the loss of the other allele to be enriched. Along the same line, are these data phased? Do you know that the nonsynonymous mutations are in the other allele or in the same allele that shows 3'UTR mutation?</p></disp-quote><p>As suggested, we have analysed copy number variation data. As mentioned in the revised Results, this &quot;showed that increased copy number was 4.1-times more common in the PCAWG data compared to allele loss. However, the incidence of copy number increase was substantially lower in the DOWN-paSNV group compared to the BG-paSNV control (Fig. S6). This points to a negative selection against duplications of genes affected by DOWNpaSNVs in cancer&quot;.</p><p>Phasing somatic mutations in cancer samples is challenging due to high genetic heterogeneity of tumour cells. This situation will likely improve in the near future with the increased use of long-read sequencing. However, with currently available data, there is no straightforward method to determine whether mutations co-occur in the same cell. We have added a note on this in the Discussion section: &quot;As long-read genomic sequencing data become increasingly available, it will be interesting to investigate whether these additional mutations occur in the same or in a different allele compared to the DOWN-paSNVs&quot;.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>To evaluate whether somatic mutations in cancer genomes are enriched with mutations in polyadenylation signal regions, the authors analyzed 1000 genomes data and PCAWG data as a control and experimental set, respectively. They observed increased enrichment of somatic mutations that may affect the function of polyA signals and confirmed that these mutations may influence the expression of the gene through a minigene expression experiment.</p><p>Strengths:</p><p>This study provides a systematic evaluation of polyA signal, which makes it valuable. Overall, the analytic approach and results are solid and supported by experimental validation.</p></disp-quote><p>Thank you.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>(1) This study uses APARENT2 as a tool to evaluate functional alteration in polyA signal sequences. Based on the original paper and the results shown in this paper, the algorithm appears to be of high quality. However, the whole study is dependent on the output of APARENT2. Therefore, it would be nice to</p><p>(a) run and show a positive control run, which can show that the algorithm works well, and (b) describe the rationale for selecting this algorithm in the main text.</p></disp-quote><p>As suggested, we have added control analyses to Fig. S1A-B, which show that APARENT2 performs well in our hands. We have described the rationale for using APARENT in the Results as follows: &quot;For each paSNV, we calculated the change in cleavage/polyadenylation efficiency using the APARENT2 neural network model, which has been shown to infer this statistic more accurately than earlier approaches [Ref23]&quot;.</p><disp-quote content-type="editor-comment"><p>(2) Are there recurrent somatic mutation calls (=exactly the same mutation across different tumor samples) in the poly(A) region of certain genes?</p></disp-quote><p>We indeed see several cases where the same cleavage/polyadenylation signal is affected by the same or different DOWN mutations in different cancer samples. This finding is now summarized in the Results section and Table S1 as follows: &quot;In several cases, including <italic>LRP1B</italic> and <italic>FOXO1</italic>, which are known to act as tumour suppressors in certain cancers, the same signal/polyadenyalation signal was disrupted by the same or different mutations in more than one sample (see columns Mut_Recurrence and Signal_Recurrence in Table S1)&quot;.</p><disp-quote content-type="editor-comment"><p>(3) The authors nicely showed that the minigene with A&gt;G mutation altered gene expression. Maybe one can reach a similar conclusion by analyzing a cancer dataset that has mutation and gene expression data? That is, genes with or without polyA mutations show different expression levels.</p></disp-quote><p>The data presented in Fig. 5A-B show that DOWN-paSNV mutations have a negative effect on the expression of endogenous tumour suppressor genes.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>Figures should be numbered in order. For example, Figure S3C is referred to in the text before S3A-B, etc.</p></disp-quote><p>We have proofread the text to fix this problem.</p><disp-quote content-type="editor-comment"><p>Adding a supplementary file with lists of genes carrying 3'UTR mutations split by effect on gene expression and cancer type would be very useful for the community.</p></disp-quote><p>We now show this in Table S1, with the caveat that we could not consistently investigate the effect of DOWN-paSNV on gene expression since the transcriptomics data are not available for all cancers.</p><disp-quote content-type="editor-comment"><p>Spelling mistake in Figure 1A - genone should be genome.</p></disp-quote><p>Fixed - thank you.</p><disp-quote content-type="editor-comment"><p>Typo in Figure 1B x-axis label +50nt should be -50nt to the left of the dashed line.</p></disp-quote><p>Fixed - thank you.</p><disp-quote content-type="editor-comment"><p>All figures use E to denote x10 but it would make the figures more readable if authors used the standard notation (x10) for all numbers with exponents and base 10.</p></disp-quote><p>Done.</p></body></sub-article></article>